Previous 10 |
home / stock / guerf / guerf news
2023 Strategic Priorities Diagnostic Imaging : increase Elucirem TM sales and strengthen international positions Interventional Imaging : prioritise Lipiodol sales with the development of innovative indications Artificial Intelligence: execution of the roadma...
GUERBET press release ( OTC:GUERF ): 1H Revenue of €371.1M (+2.2% Y/Y). Outlook: The Group is confirming its ambitions for 2022. It expects revenue growth, between 2% and 4% on a like-for-like basis and at constant exchange rates. Regarding operating...
GUERBET press release (OTC:GUERF): Q1 Revenue of €181.1M (+2.7% Y/Y). The Group is confirming its ambitions for 2022 and expects further revenue growth, between 2% and 4% on a like-for-like basis and at constant exchange rates; regarding operating profit, given the inflationary en...
GUERBET ( OTC:GUERF ): 1H Net income of €19M. More news on: GUERBET SA ORD, Earnings news and commentary, , Read more ...
GUERBET ( OTC:GUERF ): FY Net income of €46.8M. More news on: GUERBET SA ORD, Earnings news and commentary, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Guerbet SA Company Name:
GUERF Stock Symbol:
OTCMKTS Market:
H1 2024 revenue Half-yearly activity H1 revenue: €419.2m, up 11.8% at CER 1 , including an acceleration in Q2 (+14.5%) This acceleration was driven by continued catch-up in the Americas, the normalisation of orders in France and MRI sales Annual targets conf...
The CHMP issues an opinion in favour of granting an EU marketing authorisation for Elucirem™ (Gadopiclenol) with the indication of use for magnetic resonance imaging with contrast enhancement in adults and children aged 2 years and over If approved by the European...
Half-year results 2023 Acceleration of activity Half-year revenue: €378.6 million, up 2.8% at CER 1 Strong acceleration of activity in the second quarter, up 6.7% at CER Profitability in line with expectations EBITDA for the first...